<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AFREZZA- insulin human powder, metered </strong><br><strong>AFREZZA- insulin human 
			 </strong><br>Sanofi-Aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AFREZZA® safely and effectively. See full prescribing information for AFREZZA®.<br><br>AFREZZA<span class="Sup">®</span> (insulin human) Inhalation Powder<br> Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF ACUTE <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">BRONCHOSPASM</span> IN PATIENTS WITH CHRONIC <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">LUNG DISEASE</span><br><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> has been observed in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> using AFREZZA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">AFREZZA is contraindicated in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. (<a href="#S4">4</a>) </span></li>
<li><span class="Bold">Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV<span class="Sub">1</span>) to identify potential <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> in all patients. (<a href="#S2.5">2.5</a>), (<a href="#S5.1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="80%">
<col align="left" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left"><ul><li>Dosage and Administration (<a href="#S2">2</a>)</li></ul></td>
<td align="left">4/2015</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF ACUTE <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">BRONCHOSPASM</span> IN PATIENTS WITH CHRONIC <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">LUNG DISEASE</span><br><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> has been observed in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> using AFREZZA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">AFREZZA is contraindicated in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. (<a href="#S4">4</a>) </span></li>
<li><span class="Bold">Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV<span class="Sub">1</span>) to identify potential <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> in all patients. (<a href="#S2.5">2.5</a>), (<a href="#S5.1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<ul><li>AFREZZA<span class="Sup">®</span> is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.  (<a href="#S1">1</a>)</li></ul>
<p class="Highlighta">Important limitations of use: </p>
<ul>
<li>In patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, must use with a long-acting insulin. (<a href="#S1">1</a>)</li>
<li>Not recommended for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#S1">1</a>)</li>
<li>Not recommended in patients who smoke (<a href="#S1">1</a>)</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer using a single inhalation per cartridge (<a href="#S2.1">2.1</a>)</li>
<li>Administer at the beginning of a meal (<a href="#S2.2">2.2</a>)</li>
<li>Dosing must be individualized (<a href="#S2.2">2.2</a>)</li>
<li>Before initiating, perform a detailed medical history, physical examination, and spirometry (FEV<span class="Sub">1</span>) in all patients to identify potential <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (<a href="#S2.5">2.5</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta PLRHighlightText">AFREZZA is available as single-use cartridges of: (<a href="#S3">3</a>) </p>
<ul>
<li>4 units</li>
<li>8 units</li>
<li>12 units</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>During episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<a href="#S4">4</a>) </li>
<li>Chronic lung  disease, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<a href="#S4">4</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to regular human insulin or any of the AFREZZA excipients (<a href="#S4">4</a> )</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></span>:           Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> has been observed in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>.  Before initiating, perform spirometry (FEV<span class="Sub">1</span>) in all patients.  Do not use in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (<a href="#S2.5">2.5</a>, <a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</li>
<li>
<span class="Italics">Change in Insulin Regimen</span>:  Carry out under close medical supervision and increase frequency of blood glucose monitoring. (<a href="#S5.2">5.2</a>) </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span>: May be life-threatening.  Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> unawareness. (<a href="#S5.3">5.3</a>, <a href="#S6">6</a>, <a href="#S7">7</a>, <a href="#S8.6">8.6</a>, <a href="#S8.7">8.7</a>)</li>
<li>
<span class="Italics">Decline in Pulmonary Function</span>: Assess pulmonary function (e.g., spirometry) before initiating, after 6 months of therapy, and annually, even in the absence of pulmonary symptoms. (<a href="#S2.5">2.5</a>, <a href="#S5.4">5.4</a>)</li>
<li>
<span class="Italics">Lung Cancer</span>: AFREZZA should not be used in patients with active lung cancer.  In patients with a history of lung cancer or at risk for lung cancer, the benefit of AFREZZA use should outweigh this potential risk. (<a href="#S5.5">5.5</a>) </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span></span>: More patients using AFREZZA experienced <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> in clinical trials.  In patients at risk for DKA, monitor and change to alternate route of insulin delivery, if indicated. (<a href="#S5.6">5.6</a>) </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, can occur with insulin products, including AFREZZA. Discontinue AFREZZA, monitor and treat if indicated. (<a href="#S5.7">5.7</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></span>: May be life-threatening. Monitor potassium levels in patients at risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and treat if indicated. (<a href="#S5.8">5.8</a>) </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> with Concomitant Use of Thiazolidinediones (TZDs):</span> Observe for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>; consider dosage reduction or discontinuation if <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> occurs. (<a href="#S5.9">5.9</a>) </li>
</ul></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions associated with AFREZZA (2% or greater incidence) are <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span> or irritation (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at (1-800-633-1610) or FDA at (1-800-FDA-1088) or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Drugs that Affect Glucose Metabolism: Adjustment of insulin dosage may be needed. (<a href="#S7.1">7.1</a>, <a href="#S7.2">7.2</a>, <a href="#S7.3">7.3</a>) </p>
<p class="Highlighta">Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent. (<a href="#S7.3">7.3</a>, <a href="#S7.4">7.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF ACUTE <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">BRONCHOSPASM</span> IN PATIENTS WITH CHRONIC <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">LUNG DISEASE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Route of Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Information</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 AFREZZA Administration for Doses Exceeding 12 units</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment due to Drug Interactions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Lung Function Assessment Prior to Administration</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Important Administration Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> in Patients with Chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Changes in Insulin Regimen</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Decline in Pulmonary Function</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Lung Cancer</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> with Concomitant Use of PPAR-gamma Agonists</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs That May Increase the Risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs That May Decrease the Blood Glucose Lowering Effect of AFREZZA</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of AFREZZA</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs That May Affect <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> Signs and Symptoms</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy Teratogenic Effects: Pregnancy Category C</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc">11.1 AFREZZA Cartridges</a></h2>
<h2><a href="#section-10.2" class="toc">11.2 AFREZZA Inhaler</a></h2>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Overview of Clinical Studies of AFREZZA for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF ACUTE <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">BRONCHOSPASM</span> IN PATIENTS WITH CHRONIC <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">LUNG DISEASE</span></h1>
<ul>
<li><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> has been observed in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> using AFREZZA. <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li><span class="Bold">AFREZZA is contraindicated in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</span></li>
<li><span class="Bold">Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV<span class="Sub">1</span>) to identify potential <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> in all patients <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">AFREZZA<span class="Sup">®</span> is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold Underline">Limitations of Use:</span></p>
<ul>
<li>AFREZZA is not a substitute for long-acting insulin.  AFREZZA must be used in combination with long-acting insulin in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</li>
<li>AFREZZA is not recommended for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> <span class="Italics">[see <a href="#S5.6">Warning and Precautions (5.6)</a>].</span>
</li>
<li>The safety and efficacy of AFREZZA in patients who smoke has not been established.  The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Route of Administration</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">AFREZZA should only be administered via oral inhalation using the AFREZZA Inhaler. AFREZZA is administered using a single inhalation per cartridge.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Information</h2>
<p class="First">Administer AFREZZA at the beginning of the meal.</p>
<p>Dosage adjustment may be needed when switching from another insulin to AFREZZA <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Starting Mealtime Dose: </span></p>
<ul>
<li>
<span class="Italics">Insulin Naïve Individuals: </span>Start on 4 units of AFREZZA at each meal.</li>
<li>
<span class="Italics">Individuals Using Subcutaneous Mealtime (Prandial) Insulin:</span> Determine the appropriate AFREZZA dose for each meal by converting from the injected dose using Figure 1.</li>
<li>
<span class="Italics">Individuals Using Subcutaneous Pre-mixed Insulin: </span>Estimate the mealtime injected dose by dividing half of the total daily injected pre-mixed insulin dose equally among the three meals of the day. Convert each estimated injected mealtime dose to an appropriate AFREZZA dose using Figure 1. Administer half of the total daily injected pre-mixed dose as an injected basal insulin dose.</li>
</ul>
<p><span class="Bold">Figure 1. Mealtime AFREZZA Dose Conversion Table</span></p>
<div class="Figure">
<a name="FIG1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline">Mealtime Dose Adjustment</span></p>
<p>Adjust the dosage of AFREZZA based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.</p>
<p>Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness <span class="Italics"> [see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>, <span class="Italics">and <a href="#S8.6">Use in Specific Populations (8.6</a>,<a href="#S8.7">8.7)</a>]</span>.</p>
<p>Carefully monitor blood glucose control in patients requiring high doses of AFREZZA. If, in these patients, blood glucose control is not achieved with increased AFREZZA doses, consider use of subcutaneous mealtime insulin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 AFREZZA Administration for Doses Exceeding 12 units</h2>
<p class="First">For AFREZZA doses exceeding 12 units, inhalations from multiple cartridges are necessary.  To achieve the required total mealtime dose, patients should use a combination of 4 unit, 8 unit and 12 unit cartridges.  Examples of cartridge combinations for doses of up to 24 units are shown in Figure 1.  For doses above 24 units, combinations of different multiple cartridges can be used.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment due to Drug Interactions</h2>
<p class="First"> Dosage adjustment may be needed when AFREZZA is coadministered with certain drugs <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Lung Function Assessment Prior to Administration</h2>
<p class="First">AFREZZA is contraindicated in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> because of the risk of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in these patients.  Before initiating AFREZZA, perform a medical history, physical examination and spirometry (FEV<span class="Sub">1</span>) in all patients to identify potential <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Important Administration Instructions</h2>
<p class="First">See <a href="#IFU">Patient Instructions for Use</a> for complete administration instructions with illustrations.</p>
<p>Keep the inhaler level with the white mouthpiece on top and purple base on the bottom after a cartridge has been inserted into the inhaler.  Loss of drug effect can occur if the inhaler is turned upside down, held with the mouthpiece pointing down, shaken (or dropped) after the cartridge has been inserted but before the dose has been administered.  If any of the above occur, the cartridge should be replaced before use.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">AFREZZA (insulin human) Inhalation Powder is available as 4 unit, 8 unit and 12 unit single use cartridges to be administered via oral inhalation with the AFREZZA Inhaler only.  <span class="Italics">[see <a href="#S16">How Supplied/Storage and Handling (16)</a>]</span>. 						</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">AFREZZA is contraindicated in patients with the following:</p>
<ul>
<li>During episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></li>
<li>Chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), because of the risk of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> <span class="Italics">[</span>see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to regular human insulin or any of the AFREZZA excipients <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> in Patients with Chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></h2>
<p class="First">Because of the risk of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, AFREZZA is contraindicated in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> <span class="Italics">[</span>see <span class="Italics"><a href="#S4">Contraindications (4)</a>].</span></p>
<p>Before initiating therapy with AFREZZA, evaluate all patients with a medical history, physical examination and spirometry (FEV<span class="Sub">1</span>) to identify potential underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>. </p>
<p>Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> has been observed following AFREZZA dosing in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>.  In a study of patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> following AFREZZA dosing was reported in 29% (5 out of 17) and 0% (0 out of 13) of patients with and without a diagnosis of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, respectively. In this study, a mean decline in FEV<span class="Sub">1</span> of 400 mL was observed 15 minutes after a single dose in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  In a study of patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (n=8), a mean decline in FEV<span class="Sub">1</span> of 200 mL was observed 18 minutes after a single dose of AFREZZA.  The long-term safety and efficacy of AFREZZA in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> has not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Changes in Insulin Regimen</h2>
<p class="First">Glucose monitoring is essential for patients receiving insulin therapy. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. These changes should be made under close medical supervision and the frequency of blood glucose monitoring should be increased. Concomitant oral antidiabetic treatment may need to be adjusted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most common adverse reaction associated with insulins, including AFREZZA. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, may be life-threatening, or cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).</p>
<p>The timing of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually reflects the time-action profile of the administered insulin formulation.  AFREZZA has a distinct time action profile <span class="Italics">[see <a href="#S12">Clinical Pharmacology (12)</a>]</span>, which impacts the timing of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> can happen suddenly and symptoms may differ across individuals and change over time in the same individual.  Symptomatic awareness of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be less pronounced in patients with longstanding <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, in patients with diabetic nerve disease, in patients using certain medications <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>, or in patients who experience recurrent <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  Other factors which may increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>. Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be at higher risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="Italics">[see <a href="#S8.6">Use in Specific Populations ( 8.6</a>, <a href="#S8.7">8.7)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Underline">Risk Mitigation Strategies for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> </span></p>
<p>Patients and caregivers must be educated to recognize and manage <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Self-monitoring of blood glucose plays an essential role in the prevention and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. In patients at higher risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and patients who have reduced symptomatic awareness of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, increased frequency of blood glucose monitoring is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Decline in Pulmonary Function</h2>
<p class="First">AFREZZA causes a decline in lung function over time as measured by FEV<span class="Sub">1</span>.  In clinical trials excluding patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> and lasting up to 2 years, AFREZZA-treated patients experienced a small [40 mL (95% CI: -80, -1)] but greater FEV<span class="Sub">1</span> decline than comparator-treated patients. The FEV<span class="Sub">1</span> decline was noted within the first 3 months, and persisted for the entire duration of therapy (up to 2 years of observation).  In this population, the annual rate of FEV<span class="Sub">1</span> decline did not appear to worsen with increased duration of use.   The effects of AFREZZA on pulmonary function for treatment duration longer than 2 years has not been established.  There are insufficient data in long term studies to draw conclusions regarding reversal of the effect on FEV<span class="Sub">1</span> after discontinuation of AFREZZA.  The observed changes in FEV<span class="Sub">1</span> were similar in patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>Assess pulmonary function (e.g., spirometry) at baseline, after the first 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms.  In patients who have a decline of ≥ 20% in FEV<span class="Sub">1</span> from baseline, consider discontinuing AFREZZA.  Consider more frequent monitoring of pulmonary function in patients with pulmonary symptoms such as <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, breathing difficulties, or persistent or recurring <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.  If symptoms persist, discontinue AFREZZA. <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Lung Cancer</h2>
<p class="First">In clinical trials, two cases of lung cancer, one in controlled trials and one in uncontrolled trials (2 cases in 2,750 patient-years of exposure), were observed in participants exposed to AFREZZA while no cases of lung cancer were observed in comparators (0 cases in 2,169 patient-years of exposure). In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer.  Two additional cases of lung cancer (squamous cell) occurred in non-smokers exposed to AFREZZA and were reported by investigators after clinical trial completion.  These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors.  In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span></h2>
<p class="First">In clinical trials enrolling subjects with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (DKA) was more common in subjects receiving AFREZZA (0.43%; n=13) than in subjects receiving comparators (0.14%; n=3).  In patients at risk for DKA, such as those with an acute illness or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, increase the frequency of glucose monitoring and consider delivery of insulin using an alternate route of administration if indicated <span class="Italics">[see <a href="#S1">Limitations of Use (1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, can occur with insulin products, including AFREZZA.  If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, discontinue AFREZZA, treat per standard of care and monitor until symptoms and signs resolve <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>. AFREZZA is contraindicated in patients who have had <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to AFREZZA or any of its excipients <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">All insulin products, including AFREZZA, cause a shift in potassium from the extracellular to intracellular space, possibly leading to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  Untreated <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Monitor potassium levels in patients at risk for <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations and patients receiving intravenously administered insulin). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> with Concomitant Use of PPAR-gamma Agonists</h2>
<p class="First">Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, particularly when used in combination with insulin.  <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  Patients treated with insulin, including AFREZZA, and a PPAR-gamma agonist should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:</p>
<ul>
<li>Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>] </span>
</li>
<li>Decline in pulmonary function <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>] </span>
</li>
<li>Lung cancer <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>] </span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying designs, the incidence of adverse reactions reported in one clinical trial may not be easily compared to the incidence reported in another clinical trial, and may not reflect what is observed in clinical practice.</p>
<p>The data described below reflect exposure of 3017 patients to AFREZZA and include 1026 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and 1991 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The mean exposure duration was 8.17 months for the overall population and 8.16 months and 8.18 months for type 1 and 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients, respectively. In the overall population, 1874 were exposed to AFREZZA for 6 months and 724 for greater than one year. 620 and 1254 patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, respectively, were exposed to AFREZZA for up to 6 months. 238 and 486 patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, respectively, were exposed to AFREZZA for greater than one year (median exposure = 1.8 years). AFREZZA was studied in placebo and active-controlled trials (n = 3 and n = 10, respectively).</p>
<p>The mean age of the population was 50.2 years and 20 patients were older than 75 years of age. 50.8% of the population were men; 82.6% were White, 1.8% were Asian, and 4.9% were Black or African American. 9.7% were Hispanic. At baseline, the type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 16.6 years and had a mean HbA1c of 8.3%, and the type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 10.7 years and had a mean HbA1c of 8.8%. At baseline, 33.4% of the population reported <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, 32.0% reported <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> and 19.6% had a history of cardiovascular disease.</p>
<p>                  Table 1 shows common adverse reactions, excluding <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, associated with the use of AFREZZA in the pool of controlled trials in type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients. These adverse reactions were not present at baseline, occurred more commonly on AFREZZA than on placebo and/or comparator and occurred in at least 2% of patients treated with AFREZZA.</p>
<table width="75%">
<caption><span>Table 1.  Common Adverse Reactions in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (excluding <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>) Treated with AFREZZA</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th align="left"></th>
<th class="Lrule Rrule" align="center" valign="top">Placebo<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="top">AFREZZA</th>
<th class="Rrule" align="center" valign="top">Non-placebo comparators</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th class="Lrule Rrule" align="center" valign="top">(n = 290)</th>
<th class="Rrule" align="center" valign="top">(n = 1991)</th>
<th class="Rrule" align="center" valign="top">(n=1363)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Carrier particle without insulin was used as placebo <span class="Italics">[</span>see <span class="Italics"><a href="#S11">Description (11)</a></span>].</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule Toprule" align="center">19.7%</td>
<td class="Rrule Toprule" align="center">25.6%</td>
<td class="Rrule Toprule" align="center">5.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Throat pain</span> or irritation</td>
<td class="Rrule" align="center">3.8%</td>
<td class="Rrule" align="center">4.4%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">3.1%</td>
<td class="Rrule" align="center">1.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">2.7%</td>
<td class="Rrule" align="center">2.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Productive cough</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">0.7%</td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">0.6%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">0.3%</td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">1.0%</td>
</tr>
</tbody>
</table>
<p>                  Table 2 shows common adverse reactions, excluding <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, associated with the use of AFREZZA in the pool of active-controlled trials in type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients. These adverse reactions were not present at baseline, occurred more commonly on AFREZZA than on comparator, and occurred in at least 2% of patients treated with AFREZZA.</p>
<table width="75%">
<caption><span>Table 2. Common Adverse Reactions in Patients with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (excluding <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>) Treated with AFREZZA</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th class="Lrule Rrule Toprule" align="center">Subcutaneous Insulin<br>(n = 835)</th>
<th class="Rrule Toprule" align="center">AFREZZA<br>(n=1026)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule Toprule" align="center">4.9%</td>
<td class="Rrule Toprule" align="center">29.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Throat pain</span> or irritation</td>
<td class="Rrule" align="center">1.9%</td>
<td class="Rrule" align="center">5.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">4.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Pulmonary function test decreased</td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">2.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">2.5%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">1.9%</td>
<td class="Rrule" align="center">2.3%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most commonly observed adverse reaction in patients using insulin, including AFREZZA <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]. </span> The incidence of severe and non-severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> of AFREZZA versus placebo in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is shown in Table 3. A <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic episode</span> was recorded if a patient reported symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> with or without a blood glucose value consistent with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was defined as an event with symptoms consistent with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> requiring the assistance of another person and associated with either a blood glucose value consistent with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or prompt recovery after treatment for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<table width="75%">
<caption><span>Table 3.  Incidence of Severe and Non-Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in a Placebo-Controlled Study of Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(N=176)</th>
<th class="Rrule Toprule" align="center">AFREZZA<br>(N=177)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left">Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td class="Rrule Toprule" align="center">1.7%</td>
<td class="Rrule Toprule" align="center">5.1%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Non-Severe  <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td class="Rrule" align="center">30%</td>
<td class="Rrule" align="center">67%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></p>
<p>Approximately 27% of patients treated with AFREZZA reported <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, compared to approximately 5.2% of patients treated with comparator. In clinical trials, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> was the most common reason for discontinuation of AFREZZA therapy (2.8% of AFREZZA-treated patients).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Pulmonary Function Decline</span></p>
<p>In clinical trials lasting up to 2 years, excluding patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, patients treated with AFREZZA had a 40 mL (95% CI: -80, -1) greater decline from baseline in forced expiratory volume in one second (FEV<span class="Sub">1</span>) compared to patients treated with comparator anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatments. The decline occurred during the first 3 months of therapy and persisted over 2 years (Figure 2). A decline in FEV<span class="Sub">1</span> of ≥ 15% occurred in 6% of AFREZZA-treated subjects compared to 3% of comparator-treated subjects.</p>
<p><span class="Bold">Figure 2. Mean (+/-SE) Change in FEV<span class="Sub">1</span> (Liters) from Baseline for Type 1 and Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Patients</span></p>
<p><a name="FIG2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> may occur with some insulin therapies, including AFREZZA. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been attributed to the anabolic effects of insulin and the decrease in <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>. In a clinical trial of patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see <a href="#S14.3">Clinical Studies (14.3)</a>],</span> there was a mean 0.49 kg <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> among AFREZZA-treated patients compared with a mean 1.13 kg <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> among placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Underline">Antibody Production</span></p>
<p>Increases in anti-insulin antibody concentrations have been observed in patients treated with AFREZZA. Increases in anti-insulin antibodies are observed more frequently with AFREZZA than with subcutaneously injected mealtime insulins. Presence of antibody did not correlate with reduced efficacy, as measured by HbA1c and fasting plasma glucose, or specific adverse reactions.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs That May Increase the Risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with AFREZZA use may be increased with antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.  Dose adjustment and increased frequency of glucose monitoring may be required when AFREZZA is co-administered with these drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs That May Decrease the Blood Glucose Lowering Effect of AFREZZA</h2>
<p class="First">The glucose lowering effect of AFREZZA may be decreased when co-administered with  atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when AFREZZA is co-administered with these drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of AFREZZA</h2>
<p class="First">The glucose lowering effect of AFREZZA may be increased or decreased when co-administered with alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, which may sometimes be followed by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Dose adjustment and increased frequency of glucose monitoring may be required when AFREZZA is co-administered with these drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs That May Affect <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> Signs and Symptoms</h2>
<p class="First">The signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with AFREZZA.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy Teratogenic Effects: Pregnancy Category C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">AFREZZA has not been studied in pregnant women.  AFREZZA should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.</p>
<p>In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 6 through 17 (organogenesis), no major malformations were observed at up to 100 mg/kg/day (a systemic exposure 14–21 times the human systemic exposure, resulting from the maximum recommended daily dose of 99 mg AFREZZA based on AUC).</p>
<p>In pregnant rabbits given subcutaneous doses of 2, 10, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through 19 (organogenesis), adverse maternal effects were observed at all dose groups (at human systemic exposure following a 99 mg AFREZZA dose, based on AUC).</p>
<p>In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through lactation day 20 (weaning), decreased epididymis and testes weights, however, no decrease in fertility was noted, and impaired learning were observed in pups at  ≥ 30 mg/kg/day (a systemic exposure 6 times human systemic exposure at the maximum daily AFREZZA dose of 99 mg based on AUC).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Many drugs are excreted in human milk.  A study in rats indicated that the carrier is excreted in milk at approximately 10% of maternal exposure levels.  It is therefore highly likely that the insulin and carrier in AFREZZA is excreted in human milk.  A decision should be made whether to discontinue nursing or suspend use of the drug since AFREZZA has not been studied in lactating women.  </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">AFREZZA has not been studied in patients younger than 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the AFREZZA clinical studies, 381 patients were 65 years of age or older, of which 20 were 75 years of age or older.  No overall differences in safety or effectiveness were observed between patients over 65 and younger patients.</p>
<p>Pharmacokinetic/pharmacodynamic studies to assess the effect of age have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of AFREZZA has not been studied.  Frequent glucose monitoring and dose adjustment may be necessary for AFREZZA in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of AFREZZA has not been studied.  Some studies with human insulin have shown increased circulating levels of insulin in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  Frequent glucose monitoring and dose adjustment may be necessary for AFREZZA in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Excess insulin administration may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3</a>, <a href="#S5.8">5.8)</a>]</span>. 						</p>
<p>Mild episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> can usually be treated with oral glucose.  Adjustments in drug dosage, meal patterns, or exercise, may be needed.</p>
<p>Severe episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or neurologic impairment may be treated with intramuscular / subcutaneous glucagon or concentrated intravenous glucose.  After apparent clinical recovery from <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> must be corrected appropriately.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S11.1"></a><a name="section-10.1"></a><p></p>
<h2>11.1 AFREZZA Cartridges</h2>
<p class="First Paragraph">AFREZZA consists of single-use plastic cartridges filled with a white powder containing insulin (human), which is administered via oral inhalation using the AFREZZA Inhaler only.</p>
<p>AFREZZA cartridges contain human insulin produced by recombinant DNA technology utilizing a non-pathogenic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Escherichia coli </span>(K12). Chemically, human insulin has the empirical formula C<span class="Sub">257</span>H<span class="Sub">383</span>N<span class="Sub">65</span>O<span class="Sub">77</span>S<span class="Sub">6</span> and a molecular weight of 5808. Human insulin has the following primary amino acid sequence:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-03.jpg"></div>
<p>Insulin is adsorbed onto carrier particles consisting of fumaryl diketopiperazine (FDKP) and polysorbate 80.</p>
<p>AFREZZA Inhalation Powder is a dry powder supplied as 4 unit, 8 unit or 12 unit cartridges. The 4 unit cartridge contains 0.35 mg of insulin. The 8 unit cartridge contains 0.7 mg of insulin. The 12 unit cartridge contains 1 mg of insulin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S11.2"></a><a name="section-10.2"></a><p></p>
<h2>11.2 AFREZZA Inhaler</h2>
<p class="First">The AFREZZA Inhaler is breath-powered by the patient.  When the patient inhales through the device, the powder is aerosolized and delivered to the lung.  The amount of AFREZZA delivered to the lung will depend on individual patient factors.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Insulin lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The pharmacodynamic profile for orally inhaled AFREZZA 8 units relative to subcutaneously administered insulin lispro 8 units from a study in 12 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is shown in Figure 3(A). The median time to maximum effect of AFREZZA (measured by the peak rate of glucose infusion) was approximately 53 minutes (standard deviation of 74 minutes) and the effect then declined to near baseline levels by about 160 minutes.</p>
<a name="Fig3"></a><table class="Noautorules" width="100%">
<col align="left" valign="middle" width="100%">
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Despite the faster absorption of insulin (PK) from Afrezza, the onset of activity (PD) was comparable to insulin lispro.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 3. Baseline-Corrected Glucose Infusion Rate (A) and Baseline-Corrected Serum Insulin Concentrations (B) after Administration of AFREZZA or Subcutaneous Insulin Lispro in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Patients<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></td></tr>
<tr><td align="left"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-04.jpg"></td></tr>
</tbody>
</table>
<p>In a study of 32 healthy subjects, the pharmacodynamic effect of AFREZZA, measured as area under the glucose infusion rate - time curve (AUC-GIR) from an euglycemic clamp, increased in a less than dose-proportional manner. This effect has been observed for subcutaneously administered insulins, but it is unknown if the diminishing pharmacodynamic benefit at higher dosage of AFREZZA parallels that which is seen with subcutaneously administered insulin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The insulin contained in AFREZZA is regular human insulin.  Following pulmonary absorption into systemic circulation, the metabolism and elimination are comparable to regular human insulin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First">Absorption: The pharmacokinetic profiles for orally inhaled AFREZZA 8 units relative to subcutaneously administered insulin lispro 8 units from a study in 12 patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> are shown in Figure 3(B).  The maximum serum insulin concentration was reached by 12–15 minutes after inhalation of AFREZZA 8 units and serum insulin concentrations declined to baseline by approximately 180 minutes.  However, the faster absorption of insulin from Afrezza [see <a href="#Fig3">Figure 3(B)</a>] did not result in a faster onset of activity compared to insulin lispro [see <a href="#Fig3">Figure 3(A)</a>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First">Disposition:  Systemic insulin disposition (median terminal half-life) following oral inhalation of AFREZZA 4 and 32 units was 28–39 minutes, and 145 minutes for subcutaneous regular human insulin 15 units.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Carrier Particles </span></p>
<p>Clinical pharmacology studies showed that carrier particles <span class="Italics">[see <a href="#S11">Description (11)</a>]</span> are not metabolized and are eliminated unchanged in the urine following the lung absorption.  Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed.  The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Drug Interaction:  Bronchodilators and Inhaled Steroids</span></p>
<p>Albuterol increased the AUC insulin administered by AFREZZA by 25% in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  Effect of fluticasone on insulin exposures following AFREZZA administration has not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; however, no significant change in insulin exposure was observed in a study in healthy volunteers.  Frequent glucose monitoring and dose reduction may be necessary for AFREZZA if it is co-administered with albuterol.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104 week carcinogenicity study, rats were given doses up to 46 mg/kg/day of the carrier and up to 1.23 mg/kg/day of insulin, by nose-only inhalation.  No increased incidence of tumors was observed at systemic exposures equivalent to the insulin at a maximum daily AFREZZA dose of 99 mg based on a comparison of relative body surface areas across species.</p>
<p>In a 26 week carcinogenicity study, transgenic mice (Tg-ras-H2) given doses up to 75 mg/kg/day of carrier and up to 5 mg/kg/day of AFREZZA.  No increased incidence of tumors was observed. </p>
<p>AFREZZA was not genotoxic in Ames bacterial mutagenicity assay and in the chromosome aberration assay, using human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with or without metabolic activation.  The carrier alone was not genotoxic in the in vivo mouse micronucleus assay.</p>
<p>In female rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier (vehicle without insulin) beginning 2 weeks prior to mating until gestation day 7, there were no adverse effects on male fertility at doses up to 100 mg/kg/day (a systemic exposure 14–21 times that following the maximum daily AFREZZA dose of 99 mg based on AUC).  In female rats there was increased pre- and post-implantation loss at 100 mg/kg/day but not at 30 mg/kg/day (14–21 times higher systemic exposure than the maximum daily AFREZZA dose of 99 mg based on AUC).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Overview of Clinical Studies of AFREZZA for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">AFREZZA has been studied in adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in combination with basal insulin. The efficacy of AFREZZA in type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients was compared to insulin aspart in combination with basal insulin. AFREZZA has been studied in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in combination with oral antidiabetic drugs. The efficacy of AFREZZA in type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients was compared to placebo inhalation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">Patients with inadequately controlled type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a 24-week, open-label, active-controlled study to evaluate the glucose lowering effect of mealtime AFREZZA used in combination with a basal insulin.  Following a 4-week basal insulin optimization period, 344 patients were randomized to AFREZZA (n=174) or insulin aspart (n=170)administered at each meal of the day.  Mealtime insulin doses were titrated to glycemic goals for the first 12 weeks and kept stable for the last 12 weeks of the study.  At Week 24, treatment with basal insulin and mealtime AFREZZA provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin of 0.4%.  AFREZZA provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. More subjects in the insulin aspart group achieved the HbA1c target of ≤7% (Table 4).</p>
<table width="75%">
<caption><span>Table 4.  Results at Week 24 in an Active-Controlled Study of Mealtime AFREZZA plus Basal Insulin in Adults with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Efficacy Parameter</th>
<th class="Rrule" align="center" valign="middle">AFREZZA + Basal Insulin (N=174)</th>
<th class="Rrule" align="center">Insulin Aspart + Basal Insulin<br>(N=170)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Adjusted mean was obtained using a Mixed Model Repeated Measures (MMRM) approach with HbA1c or FPG as the dependent variable and treatment, visit, region, basal insulin stratum, and treatment by visit interaction as fixed factors, and corresponding baseline as a covariate.  An autoregression (1) [AR(1)] covariance structure was used.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Data at 24 weeks were available from 131 (75 %) and 150 (88% ) subjects randomized to the AFREZZA and insulin aspart groups, respectively.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>The  percentage was calculated based on the number of patients randomized to the trial.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (adjusted mean<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>)</td>
<td class="Rrule" align="center">7.94</td>
<td class="Rrule" align="center">7.92</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean<a href="#footnote-3" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>)</td>
<td class="Rrule" align="center">-0.21</td>
<td class="Rrule" align="center">-0.40</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Difference from insulin aspart (adjusted mean<a href="#footnote-3" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-4" class="Sup">†</a>)</td>
<td class="Rrule" align="center" colspan="2">0.19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  (95% CI)</td>
<td class="Rrule" align="center" colspan="2">(0.02, 0.36)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Percentage of patients achieving HbA1c ≤ 7%<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">13.8</td>
<td class="Rrule" align="center">27.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (adjusted mean<a href="#footnote-3" class="Sup">*</a>)</td>
<td class="Rrule" align="center">153.9</td>
<td class="Rrule" align="center">151.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean<a href="#footnote-3" class="Sup">*</a><span class="Sup">, </span><a href="#footnote-4" class="Sup">†</a>)</td>
<td class="Rrule" align="center">-25.3</td>
<td class="Rrule" align="center">10.2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Difference from insulin aspart (adjusted mean<a href="#footnote-3" class="Sup">*</a><span class="Sup">, </span><a href="#footnote-4" class="Sup">†</a>)</td>
<td class="Rrule" align="center" colspan="2">-35.4</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  (95% CI)</td>
<td class="Rrule" align="center" colspan="2">(-56.3, -14.6)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">A total of 479 adult patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on optimal/maximally tolerated doses of metformin only, or 2 or more oral antidiabetic (OAD) agents participated in a 24-week, double-blind, placebo-controlled study.  Following a 6-week run-in period, 353 patients were randomized to AFREZZA (n=177) or an inhaled placebo powder without insulin (n=176).  Insulin doses were titrated for the first 12 weeks and kept stable for the last 12 weeks of the study.  OADs doses were kept stable.  At Week 24, treatment with AFREZZA plus OADs provided a mean reduction in HbA1c that was statistically significantly greater compared to the HbA1c reduction observed in the placebo group (Table 5).</p>
<table width="75%">
<caption><span>Table 5.  Results at Week 24 in a Placebo-Controlled Study of AFREZZA in Adults with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Oral Antidiabetic Agents</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Efficacy Parameter</th>
<th class="Rrule" align="center">AFREZZA + Oral Anti-Diabetic Agents<br>(N=177)</th>
<th class="Rrule" align="center">Placebo + Oral Anti-Diabetic Agents<br>(N=176)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Adjusted mean was obtained using a Mixed Model Repeated Measures (MMRM) approach with HbA1c or FPG as the dependent variable and treatment, visit, region, and treatment by visit interaction as fixed factors, and corresponding baseline as a covariate.  An autoregression (1) [AR(1)] covariance structure was used.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Data at 24 weeks without  rescue therapy were available from 139 (79%) and 129 (73%) subjects randomized to the AFREZZA and placebo groups, respectively.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>The percentage was calculated based on the number of patients randomized to the trial. </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (adjusted mean<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>)</td>
<td class="Rrule" align="center">8.25</td>
<td class="Rrule" align="center">8.27</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean<a href="#footnote-6" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>)</td>
<td class="Rrule" align="center">-0.82</td>
<td class="Rrule" align="center">-0.42</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean<a href="#footnote-6" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-7" class="Sup">†</a>)<br>  (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-0.40<br>(-0.57, -0.23)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Percentage (%) of patients achieving HbA<span class="Sub">1C</span> ≤7%<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">32.2</td>
<td class="Rrule" align="center">15.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Baseline (adjusted mean<a href="#footnote-6" class="Sup">*</a>)</td>
<td class="Rrule" align="center">175.9</td>
<td class="Rrule" align="center">175.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change from baseline (adjusted mean<a href="#footnote-6" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-7" class="Sup">†</a>)</td>
<td class="Rrule" align="center">-11.2</td>
<td class="Rrule" align="center">-3.8</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  Difference from placebo (adjusted mean<a href="#footnote-6" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-7" class="Sup">†</a>)<br>  (95% CI)</td>
<td class="Rrule" align="center" colspan="2">-7.4<br>(-18.0, 3.2)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First Paragraph">AFREZZA (insulin human) Inhalation Powder is available as 4 unit, 8 unit and 12 unit single-use cartridges. Three cartridges are contained in a single cavity of a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> strip. Each card contains 5 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> strips separated by perforations for a total of 15 cartridges. For convenience, the perforation allows users to remove a single strip containing 3 cartridges. Two cards of the same cartridge strength are packaged in a foil laminate overwrap (30 cartridges per foil package).</p>
<p>The cartridges are color-coded, blue for 4 units, green for 8 units and yellow for 12 units. Each cartridge is marked with "<span class="Italics">afrezza</span>" and "4 units", "8 units" or "12 units".</p>
<p>The AFREZZA Inhaler is individually packaged in a translucent overwrap. The inhaler is fully assembled with a removable mouthpiece cover. The AFREZZA Inhaler can be used for up to 15 days from the date of first use. After 15 days of use, the inhaler must be discarded and replaced with a new inhaler.</p>
<p>AFREZZA is available in the following configurations:</p>
<ul>
<li>NDC 0024-5874-90, AFREZZA (insulin human) Inhalation Powder: 90 − 4 unit cartridges and 2 inhalers</li>
<li>NDC 0024-5878-90, AFREZZA (insulin human) Inhalation Powder: 90 − 8 unit cartridges and 2 inhalers</li>
<li>NDC 0024-5884-63, AFREZZA (insulin human) Inhalation Powder: 90 cartridges; 60 – 4 unit cartridges and 30 − 8 unit cartridges and 2 inhalers</li>
<li>NDC 0024-5882-36, AFREZZA (insulin human) Inhalation Powder: 90 cartridges; 30 – 4 unit cartridges and 60 − 8 unit cartridges and 2 inhalers</li>
<li>NDC 0024-5880-18, AFREZZA (insulin human) Inhalation Powder: 180 cartridges; 90 - 4 unit cartridges and 90 – 8 unit cartridges and 2 inhalers</li>
<li>NDC 0024-5894-63, AFREZZA (insulin human)Inhalation Powder: 90 cartridges;  60 – 8 unit cartridges and 30 - 12 unit cartridges and 2 inhalers</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Not in Use: Refrigerated Storage 2–8ºC (36–46ºF)</p>
<table class="Noautorules" width="65%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>If a foil package, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card or strip is not refrigerated, the contents must be used within 10 days.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Sealed (Unopened) Foil Package</td>
<td class="Botrule Rrule Toprule" align="left">May be stored until the Expiration Date<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Sealed (Unopened) <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards + Strips</td>
<td class="Botrule Rrule Toprule" align="left">May be stored for 1 month<a href="#footnote-9" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p>In Use: Room Temperature Storage 25ºC (77ºF), excursions permitted 15–30ºC (59–86ºF)</p>
<table class="Noautorules" width="65%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td class="Lrule Rrule Toprule" align="left">Sealed (Unopened) <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards + Strips</td>
<td class="Rrule Toprule" align="left">Must be used within 10 days</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Opened Strips</td>
<td class="Botrule Rrule Toprule" align="left">Must be used within 3 days</td>
</tr>
</tbody>
</table>
<p>Do not put a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card or strip back into the refrigerator after being stored at room temperature</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">Inhaler Storage:</span></p>
<p>Store at 2–25ºC (36–77ºF); excursions permitted. Inhaler may be stored refrigerated, but should be at room temperature before use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<p class="First"><span class="Bold">Handling:</span></p>
<p>Before use, cartridges should be at room temperature for 10 minutes.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First Paragraph">See FDA-approved patient labeling (<a href="#MG">Medication Guide</a>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Instructions</span></p>
<p>Instruct patients to read the Medication Guide before starting AFREZZA therapy and to reread it each time the prescription is renewed, because information may change. Instruct patients to inform their healthcare provider or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.</p>
<p>Inform patients of the potential risks and benefits of AFREZZA and of alternative modes of therapy. Inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and assessment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> complications. Advise patients to seek medical advice promptly during periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, as medication requirements may change.</p>
<p>Instruct patients to use AFREZZA only with the AFREZZA inhaler.</p>
<p>Inform patients that the most common adverse reactions associated with the use of AFREZZA are <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span> or irritation.</p>
<p>Advise women with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> to inform their physician if they are pregnant or are planning to become pregnant while using AFREZZA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> in Patients with Chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></span></p>
<p>Advise patients to inform their physicians if they have a history of <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, because AFREZZA should not be used in patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, or other chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>(s)) <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>Advise patients that if they experience any respiratory difficulty after inhalation of AFREZZA, they should report it to their physician immediately for assessment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>Instruct patients on self-management procedures including glucose monitoring, proper inhalation technique, and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> especially at initiation of AFREZZA therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals.</p>
<p>Instruct patients on the management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Inform patients that their ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Advise patients who have frequent <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or reduced or absent warning signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> to use caution when driving or operating machinery <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First"><span class="Bold">Decline in Pulmonary Function and Monitoring </span></p>
<p>Inform patients that AFREZZA can cause a decline in lung function and their lung function will be evaluated by spirometry before initiation of AFREZZA treatment <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First"><span class="Bold">Lung Cancer</span></p>
<p>Inform patients to promptly report any signs or symptoms potentially related to lung cancer <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span></span></p>
<p>Instruct patients to carefully monitor their blood glucose during illness, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and other risk situations for <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> and to contact their healthcare provider if their blood glucose control worsens <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> can occur with insulin therapy including AFREZZA. Inform patients on the symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">AFREZZA is a registered trademark owned by MannKind Corporation<br>						Patented:  http://www.mannkindcorp.com/our-technology-patent-notices.htm<br>					 						Manufactured by:</p>
<p>MannKind Corporation<br> Danbury, CT 06810</p>
<p>Distributed by:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>07/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-17"></a><p></p>
<h1>Medication Guide<br>AFREZZA® (uh-FREZZ-uh)<br>(insulin human) inhalation powder</h1>
<p class="First"><a name="What1"></a><span class="Bold">What is the most important information I should know about AFREZZA?</span></p>
<p><span class="Bold">AFREZZA can cause serious side effects, including:</span></p>
<ul><li>
<span class="Bold">Sudden lung problems (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span>). Do not use AFREZZA if you have long-term (chronic) lung problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>).</span> Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.</li></ul>
<p><span class="Bold">What is AFREZZA?</span></p>
<ul>
<li>AFREZZA is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</li>
<li>AFREZZA is not for use in place of long-acting insulin. AFREZZA must be used with long-acting insulin in people who have type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</li>
<li>AFREZZA is not for use to treat <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</li>
<li>It is not known if AFREZZA is safe and effective for use in people who smoke. AFREZZA is not for use in people who smoke or have recently stopped smoking (less than 6 months).</li>
<li>It is not known if AFREZZA is safe and effective in children under 18 years of age.</li>
</ul>
<p><span class="Bold">Who should not use AFREZZA?</span></p>
<p><span class="Bold">Do not use AFREZZA if you:</span></p>
<ul>
<li>have chronic lung problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>.</li>
<li>are allergic to regular human insulin or any of the ingredients in AFREZZA. See the end of this Medication Guide for a complete list of ingredients in AFREZZA.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before using </span><span class="Bold">AFREZZA?</span></p>
<p><span class="Bold">Before using AFREZZA, tell your healthcare provider about all your medical conditions, including if you:</span></p>
<ul>
<li>have lung problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span></li>
<li>have or have had lung cancer</li>
<li>are using any inhaled medications</li>
<li>smoke or have recently stopped smoking</li>
<li>have kidney or liver problems</li>
<li>are pregnant, planning to become pregnant, or are breastfeeding. AFREZZA may harm your unborn or breastfeeding baby.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.</p>
<p><span class="Bold">Before you start using AFREZZA, talk to your healthcare provider about low blood sugar and how to manage it. </span></p>
<p><span class="Bold">How should I use AFREZZA?</span></p>
<ul>
<li>Read the detailed<span class="Bold"> Instructions for Use </span>that comes with your AFREZZA.</li>
<li>Take AFREZZA exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much AFREZZA to use and when to use it.</li>
<li>Know the strength of AFREZZA you use. <span class="Bold">Do not</span> change the amount of AFREZZA you use unless your healthcare provider tells you to.</li>
<li>Take AFREZZA at the beginning of your meal.</li>
<li>
<span class="Bold">Check your blood sugar levels. </span>Ask your healthcare provider what your blood sugar should be and when you should check your blood sugar levels.</li>
<li><span class="Bold">Keep AFREZZA and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">Your dose of AFREZZA may need to change because of: </span></p>
<ul><li>Change in level of physical activity or exercise, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss, increased stress, illness, change in diet, or because of other medicines you take.</li></ul>
<p><span class="Bold">What should I avoid while using AFREZZA?</span></p>
<p><span class="Bold">While using AFREZZA do not:</span></p>
<ul>
<li>drive or operate heavy machinery, until you know how AFREZZA affects you</li>
<li>drink alcohol or use over-the-counter medicines that contain alcohol</li>
<li>smoke</li>
</ul>
<p><span class="Bold">What are the possible side effects of AFREZZA?</span></p>
<p><span class="Bold">AFREZZA may cause serious side effects that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including: </span></p>
<p><span class="Bold">See "<a href="#What1">What is the most important information I should know about AFREZZA?</a>"</span></p>
<ul>
<li>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). </span>Signs and symptoms that may indicate low blood sugar include:<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or light-headedness, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, fast heartbeat, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood change</span>, <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span>.</li></ul>
</li>
<li>
<span class="Bold">decreased lung function. </span>Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it and yearly after that.</li>
<li>
<span class="Bold">lung cancer. </span>In studies of AFREZZA in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, lung cancer occurred in a few more people who were taking AFREZZA than in people who were taking other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medications. There were too few cases to know if lung cancer was related to AFREZZA. If you have lung cancer, you and your healthcare provider should decide if you should use AFREZZA.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. </span>Talk to your healthcare provider if you have an illness. Your AFREZZA dose or how often you check your blood sugar may need to be changed.</li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</span><ul class="Disc"><li>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> over your whole body, trouble breathing, a fast heartbeat, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</li></ul>
</li>
<li><span class="Bold">low potassium in your blood (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>).</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> Taking certain <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> pills called thiazolidinediones or "TZDs" with AFREZZA may cause <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in some people. This can happen even if you have never had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or heart problems before. If you already have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> it may get worse while you take TZDs with AFREZZA. Your healthcare provider should monitor you closely while you are taking TZDs with AFREZZA. Tell your healthcare provider if you have any new or worse symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> including:<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles or feet, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</li></ul>Treatment with TZDs and AFREZZA may need to be changed or stopped by your healthcare provider if you have new or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</li>
</ul>
<p><span class="Bold">Get emergency medical help if you have:</span></p>
<ul><li>trouble breathing, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, fast heartbeat, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, tongue, or throat, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</li></ul>
<p><span class="Bold">The most common side effects of AFREZZA include:</span></p>
<ul><li>low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li></ul>
<p><span class="Bold">These are not all the possible side effects of AFREZZA. </span>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).</p>
<p><span class="Bold">General information about the safe and effective use of AFREZZA.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use AFREZZA for a condition for which it was not prescribed. Do not give AFREZZA to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about AFREZZA. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about AFREZZA that is written for health professionals. For more information, go to www.AFREZZA.com or call sanofi-aventis 1-800-633-1610.</p>
<p><span class="Bold">What are the ingredients in AFREZZA?</span></p>
<p><span class="Bold">Active ingredient:</span> human insulin</p>
<p><span class="Bold">Inactive ingredients:</span> fumaryl diketopiperazine, polysorbate 80</p>
<p><span class="Bold">Manufactured By: </span>MannKind Corporation</p>
<p>AFREZZA<span class="Sup">®</span> is a registered trademark owned by MannKind Corporation</p>
<p>Patented: http://www.mannkindcorp.com/our-technology-patent-notices.htm</p>
<p>MannKind Corporation<br> Danbury, CT 06810</p>
<p><span class="Bold">Distributed by:</span><br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="IFU"></a><a name="section-18"></a><p></p>
<h1>Instructions for Use<br>AFREZZA® (uh-FREZZ-uh)<br>(insulin human) inhalation powder</h1>
<p class="First">Read this Instructions for Use before you start using AFREZZA and each time you get a new AFREZZA inhaler. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">Your healthcare provider should show you how to use your AFREZZA inhaler the right way before you use it for the first time.</span></p>
<p><span class="Bold">Important information about AFREZZA:</span></p>
<ul><li>
<span class="Bold">AFREZZA comes in 3 strengths </span>(See <a href="#FIGA">Figure A</a>):<ul>
<li>4 units (blue cartridge)</li>
<li>8 units (green cartridge)</li>
<li>12 units (yellow cartridge)</li>
</ul>
<a name="FIGA"></a><table class="Noautorules" width="75%">
<col align="left" valign="top" width="75%">
<col align="left" valign="top" width="25%">
<tbody class="Headless"><tr>
<td align="left"></td>
<td align="left">(Figure A)</td>
</tr></tbody>
</table>
<p class="First"><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-05.jpg"></p>
</li></ul>
<ul>
<li>If your prescribed AFREZZA dose is higher than 12 units, you will need to use more than 1 cartridge.</li>
<li>If you need to use more than 1 cartridge for your dose, throw away the used cartridge before getting a new one. You can tell when a cartridge has been used, because the cup has moved to the center.</li>
<li>
<span class="Bold">Do not try to open the </span><span class="Bold">AFREZZA cartridges. </span>The AFREZZA Inhaler opens the cartridge automatically during use.</li>
<li>
<span class="Bold">AFREZZA cartridges should only be used with the AFREZZA Inhaler.</span><span class="Bold"> Do not </span>try to breathe in the AFREZZA insulin powder in any other way. <span class="Bold">Do not</span> put cartridges in your mouth and <span class="Bold">do not</span> swallow cartridges.</li>
<li>Use only 1 AFREZZA Inhaler at a time. The same inhaler should be used for the 4 unit, 8 unit or 12 unit cartridges.</li>
<li>Throw away your AFREZZA Inhaler after 15 days and get a new one.</li>
</ul>
<p><span class="Bold">If you are having problems with your </span><span class="Bold">AFREZZA inhaler or if it breaks and you need a new one, call 1-800-633-1610.</span></p>
<p><span class="Bold">Know your AFREZZA<span class="Sup">® </span>inhaler:</span></p>
<p><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-06.jpg"></p>
<p><span class="Bold"><span class="Bold">Know your AFREZZA<span class="Sup">®</span> cartridges:</span></span></p>
<p><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-07.jpg"></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr><td align="left" colspan="2" valign="top">
<p class="First"><span class="Bold">How to take your dose of AFREZZA: </span></p>
<p>Always be sure you have the right number of AFREZZA cartridges for your dose available before you start. AFREZZA cartridges must only be used with the AFREZZA Inhaler.</p>
</td></tr>
<tr><td class="Botrule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Step 1: Select the AFREZZA cartridges for your dose</span></p></td></tr>
<tr>
<td class="Botrule" align="left" colspan="2" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-08.jpg"></p></td>
<td colspan="2" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">If your prescribed AFREZZA<span class="Sup">® </span>dose is more than 12 units</span> you will need to use <span class="Bold">more than 1 cartridge</span> to get your right dose.</p></td></tr>
<tr><td class="Botrule" align="center" colspan="2" valign="top">
<p class="First"> <br> <br>Use the dosage chart below to determine the least number of AFREZZA<span class="Sup">®</span> cartridges you can use for your dose. Other cartridge combinations can be used.</p>
<p><a name="FIGB"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-09.jpg"></p>
<p>(Figure B)</p>
</td></tr>
<tr><td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Example:</span></p></td></tr>
<tr><td class="Botrule" align="left" colspan="2"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-10.jpg"></p></td></tr>
<tr><td class="Botrule" align="left" colspan="2">
<p class="First"><span class="Bold">Select Cartridges</span></p>
<p><span class="Bold">Important: Use the AFREZZA dose chart above (See <a href="#FIGB">Figure B</a>)</span> to help you choose the right number of AFREZZA cartridges needed for your dose.</p>
</td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-11.jpg"></p></td>
<td class="Botrule" align="left" valign="top"><p class="First"><span class="Bold">Open Packages</span><br><br>Remove a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card from the foil package.<br><br>Tear along perforation to remove one strip.</p></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-12.jpg"></p></td>
<td class="Botrule" align="left" valign="top">
<p class="First"><span class="Bold">Push Cartridges to Remove</span></p>
<p>Remove a cartridge from the strip by pressing on the clear side to push the cartridge out. Remove the right number of cartridges for your dose. Pushing on the cup will not damage the cartridge.</p>
<p><span class="Bold">AFREZZA cartridges left over in an opened strip must be used within 3 days. </span></p>
</td>
</tr>
<tr><td class="Botrule" align="center" colspan="2" valign="top"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-13.jpg"></td></tr>
<tr><td class="Botrule" align="left" colspan="2" valign="top">
<p class="First"><span class="Bold">Before Proceeding: </span></p>
<p>Check that you have the right AFREZZA cartridge(s) for your dose.</p>
<p>Use only 1 inhaler for multiple cartridges. Throw away your AFREZZA inhaler after 15 days and get a new one.</p>
</td></tr>
</tbody>
</table>
<table class="Noautorules" width="65%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Step 2: Loading a cartridge</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-14.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Hold Inhaler</span></p>
<p>Hold the inhaler level in one (1) hand with the white mouthpiece on the top and purple base on the bottom.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-15.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Open Inhaler</span></p>
<p>Open the inhaler by lifting the white mouthpiece to a vertical position.</p>
<p>Before you put the AFREZZA cartridge in your inhaler, make sure it has been at <span class="Bold">room temperature for 10 minutes</span>.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-16.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Place Cartridge</span></p>
<p>Hold the cartridge with the cup facing down.</p>
<p>Line up the cartridge with the opening in the inhaler. The pointed end of the cartridge should line up with the pointed end in the inhaler.</p>
<p>Place the cartridge into the inhaler. Be sure that the cartridge lies flat in the inhaler.</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-17.jpg"></p></td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-18.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Close Inhaler</span></p>
<p>Lower the mouthpiece to close the inhaler (this will open the drug cartridge).</p>
<p>You should feel a snap when the inhaler is closed.</p>
</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="72%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Step 3: Inhaling AFREZZA</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-19.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Remove the Mouthpiece Cover</span></p>
<p><span class="Bold">Important</span><span class="Bold">: </span> Keep the inhaler level during and after removal of the purple mouthpiece cover.</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-20.jpg"></p></td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-21.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Exhale</span></p>
<p>Hold the inhaler away from your mouth and fully blow out (exhale).</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-22.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Position Inhaler in Mouth</span></p>
<p>Keeping your head level, place the mouthpiece in your mouth and <span class="Bold">tilt the inhaler down towards your chin, as shown.</span></p>
<p>Close your lips around the mouthpiece to form a seal.</p>
<p><span class="Bold">Tilt the inhaler downward while keeping your head level.</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-23.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Inhale Deeply and Hold Breath</span></p>
<p>With your mouth closed around the mouthpiece, <span class="Bold">inhale deeply through the inhaler</span>.</p>
<p><span class="Bold">Hold your breath</span> for as long as comfortable and at the same time remove the inhaler from your mouth. After holding your breath, exhale and continue to breathe normally.</p>
</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="72%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Step 4: Removing a used cartridge</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-24.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Replace Mouthpiece Cover</span></p>
<p>Place the purple mouthpiece cover back onto the inhaler.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-25.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Open Inhaler</span></p>
<p>Open the inhaler by lifting up the white mouthpiece.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-26.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Remove Cartridge</span></p>
<p>Remove the cartridge from the purple base.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-27.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Throw away the Cartridge</span></p>
<p>Throw away the used cartridge in your regular household trash.</p>
</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="72%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Multiple cartridge dosing</span></p></td></tr>
<tr>
<td class="Botrule Lrule Toprule" align="left" valign="top"><p class="First"><span class="Bold">If you need more than one (1) AFREZZA cartridge for your dose, See the AFREZZA dosage chart above (<a href="#FIGB">Figure B</a>).</span></p></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-28.jpg"></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Repeat steps 2 through 4 for each AFREZZA cartridge you need for your prescribed AFREZZA dose.</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-29.jpg"></td></tr>
</tbody>
</table>
<table class="Noautorules" width="72%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold">How should I store AFREZZA?</span></p></td></tr>
<tr><td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-30.jpg"></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">*If a foil package, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card or strip is not refrigerated, the contents must be used within 10 days </p></td></tr>
<tr><td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-31.jpg"></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Do not put a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card or strip back into the refrigerator after being stored at room temperature</p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-32.jpg"></p></td></tr>
</tbody>
</table>
<table class="Noautorules" width="70%">
<col align="left" valign="top" width="100%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold">Caring for your AFREZZA inhaler:</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-33.jpg"></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-34.jpg"></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-35.jpg"></p></td></tr>
</tbody>
</table>
<table class="Noautorules" width="95%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="48%">
<tbody class="Headless">
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><p class="First"><span class="Bold">Switching between AFREZZA and injected insulin:</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-36.jpg"></td>
<td class="Botrule Rrule" align="left" colspan="2"><span class="Bold">Contact your healthcare provider before switching insulins.<br>AFREZZA<span class="Sup">®</span> is a mealtime insulin.<br>Do not switch from AFREZZA to a long acting insulin.<br>Do not switch from a long acting insulin to AFREZZA<span class="Sup">®</span>.</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-37.jpg"></td>
<td class="Botrule Rrule" align="center" valign="top"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-38.jpg"></td>
</tr>
</tbody>
</table>
<p>This Medication Guide and Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>AFREZZA<span class="Sup">®</span> is a registered trademark owned by MannKind Corporation</p>
<p>Patented: See http://www.mannkindcorp.com/our-technology-patent-notices.htm</p>
<p>Manufactured by:</p>
<p>MannKind Corporation<br> Danbury, CT 06810</p>
<p>Distributed by:</p>
<p>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>Approved: 07/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 90 Cartridge Carton</h1>
<p class="First">NDC 0024-5874-90<br>Rx ONLY</p>
<p><span class="Bold">For FPO Only</span></p>
<p><span class="Bold Italics">afrezza</span><span class="Sub">®</span><br><span class="Italics">(insulin human)<br> Inhalation Powder</span></p>
<p><span class="Italics">Each blue cartridge<br>approximates 4 units<br>of injected insulin</span></p>
<p><span class="Bold">SANOFI</span></p>
<p><span class="Bold">4<br>units per<br>cartridge</span></p>
<p><span class="Bold">90 cartridges</span></p>
<p><span class="Bold">FOR ORAL INHALATION ONLY</span></p>
<p>Carton Contains:<br><span class="Bold">90 – 4 unit Cartridges + 2 Inhalers</span></p>
<p>Dispense the enclosed Medicaton Guide<br>to each patient</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 90 Cartridge Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-39.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 – 4 Unit/30 – 8 Unit Kit Carton</h1>
<p class="First">NDC 0024-5884-63<br>Rx ONLY</p>
<p><span class="Bold">For FPO Only</span></p>
<p><span class="Bold Italics">afrezza</span><span class="Sub">®</span><br><span class="Italics">(insulin human)<br> Inhalation Powder</span></p>
<p><span class="Italics">Each blue cartridge<br>approximates 4 units<br>of injected insulin</span></p>
<p><span class="Italics">Each green cartridge<br>approximates 8 units<br>of injected insulin</span></p>
<p><span class="Bold">SANOFI</span></p>
<p><span class="Bold">4<br>units per<br>cartridge</span></p>
<p><span class="Bold">8<br>units per<br>cartridge</span></p>
<p><span class="Bold">90 cartridges</span></p>
<p><span class="Bold">FOR ORAL INHALATION ONLY</span></p>
<p>Carton Contains:<br><span class="Bold">60 – 4 unit Cartridges | + 2 Inhalers<br>30 – 8 unit Cartridges</span></p>
<p>Dispense the enclosed<br> Medicaton Guide<br>to each patient</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 – 4 Unit/30 – 8 Unit Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-40.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 – 4 Unit/60 – 8 Unit Kit Carton</h1>
<p class="First">NDC 0024-5882-36<br>Rx ONLY</p>
<p><span class="Bold">For FPO Only</span></p>
<p><span class="Bold Italics">afrezza</span><span class="Sub">®</span><br><span class="Italics">(insulin human)<br> Inhalation Powder</span></p>
<p><span class="Italics">Each blue cartridge<br>approximates 4 units<br>of injected insulin</span></p>
<p><span class="Italics">Each green cartridge<br>approximates 8 units<br>of injected insulin</span></p>
<p><span class="Bold">SANOFI</span></p>
<p><span class="Bold">4<br>units per<br>cartridge</span></p>
<p><span class="Bold">8<br>units per<br>cartridge</span></p>
<p><span class="Bold">90 cartridges</span></p>
<p><span class="Bold">FOR ORAL INHALATION ONLY</span></p>
<p>Carton Contains:<br><span class="Bold">30 – 4 unit Cartridges | + 2 Inhalers<br>60 – 8 unit Cartridges</span></p>
<p>Dispense the enclosed<br> Medicaton Guide<br>to each patient</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 – 4 Unit/60 – 8 Unit Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-41.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 – 8 Unit/30 – 12 Unit Kit Carton</h1>
<p class="First">NDC 0024-5894-63<br>Rx ONLY</p>
<p><span class="Bold">For FPO Only</span></p>
<p><span class="Bold Italics">afrezza</span><span class="Sub">®</span><br><span class="Italics">(insulin human)<br> Inhalation Powder</span></p>
<p><span class="Italics">Each green cartridge<br>approximates 8 units<br>of injected insulin</span></p>
<p><span class="Italics">Each yellow cartridge<br>approximates 12 units<br>of injected insulin</span></p>
<p><span class="Bold">SANOFI</span></p>
<p><span class="Bold">8<br>units per<br>cartridge</span></p>
<p><span class="Bold">12<br>units per<br>cartridge</span></p>
<p><span class="Bold">90 cartridges</span></p>
<p><span class="Bold">FOR ORAL INHALATION ONLY</span></p>
<p>Carton Contains:<br><span class="Bold">60 – 8 unit Cartridges | + 2 Inhalers<br>30 – 12 unit Cartridges</span></p>
<p>Dispense the enclosed<br> Medication Guide<br>to each patient</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 – 8 Unit/30 – 12 Unit Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76fb46f1-82db-40da-ba19-b3a7b0bd78ff&amp;name=afrezza-42.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5874</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Insulin Human</strong> (Insulin Human) </td>
<td class="formItem">Insulin Human</td>
<td class="formItem">4 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Fumaryl Diketopiperazine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5874-90</td>
<td class="formItem">90  in 1 PACKAGE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5884</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5884-63</td>
<td class="formItem">90  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">60 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 PACKAGE </td>
<td class="formItem">30 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">4 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">8 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 PACKAGE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5882</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5882-36</td>
<td class="formItem">90  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">30 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">60 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">4 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">8 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5894</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5894-63</td>
<td class="formItem">90  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">60 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">30 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">8 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>AFREZZA 		
					</strong><br><span class="contentTableReg">insulin human powder, metered</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">12 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FUMARYL DIKETOPIPERAZINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022472</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi-Aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mannkind Corporation</td>
<td class="formItem"></td>
<td class="formItem">099981040</td>
<td class="formItem">MANUFACTURE(0024-5874, 0024-5884, 0024-5882, 0024-5894), ANALYSIS(0024-5874, 0024-5884, 0024-5882, 0024-5894, 0024-5894, 0024-5874), LABEL(0024-5874, 0024-5884, 0024-5882), PACK(0024-5884, 0024-5882, 0024-5894)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f222a734-081c-4098-a973-a3274e29e7ac</div>
<div>Set id: 76fb46f1-82db-40da-ba19-b3a7b0bd78ff</div>
<div>Version: 5</div>
<div>Effective Time: 20150702</div>
</div>
</div> <div class="DistributorName">Sanofi-Aventis U.S. LLC</div></p>
</body></html>
